Bio-techne CORP 10-Q quarterly reports

Bio-Techne Corporation's Q3 2026 results show a slight decrease in net sales and a dip in operating income, attributed to product mix and prior year non-recurring items.

Bio-Techne Corporation reports flat net sales for the quarter ended December 31, 2025, with diluted EPS increasing to $0.24, driven by cost management and divestitures.

Bio-Techne Corporation reported a 1% decrease in net sales to $286.6 million for the first quarter of fiscal 2026, yet saw net earnings climb to $38.2 million, driven by improved gross margins and strategic divestitures.

Bio-Techne Corporation reports a 4% increase in net sales but a decrease in net earnings for the third quarter of fiscal year 2025, primarily due to a non-recurring arbitration award.

Bio-Techne Corporation reports a 9% increase in net sales for the second quarter of fiscal year 2025, driven by strong performance in its Diagnostics and Spatial Biology segment and improving biopharma market conditions.

Bio-Techne Corporation saw a 5% increase in net sales but a decrease in net earnings for the quarter ended September 30, 2024, compared to the same period last year.

Bio-Techne's third-quarter results show a slight revenue increase but a significant drop in net earnings due to restructuring, acquisition costs, and unfavorable volume in Protein Sciences.

Bio-Techne's second-quarter results show flat sales and decreased earnings, impacted by restructuring and acquisition costs.